Core Insights - The rise of GLP-1 weight-loss drugs is significantly impacting the food industry, with a projected $12 billion cost to Big Food over the next decade as consumer preferences shift towards healthier options [2][3]. Group 1: Market Impact - Approximately 20% of U.S. households now have someone using a GLP-1 drug, with usage more than doubling in the past year [3]. - These medications can reduce calorie intake by about 40%, particularly from sugar and alcohol, leading to a decline in demand for high-calorie, processed foods [3][8]. - The increased usage of GLP-1 drugs is contributing to a drop in sugar demand, resulting in prices reaching five-year lows [4]. Group 2: Corporate Responses - Companies like PepsiCo and Coca-Cola are adapting their strategies in response to the popularity of GLP-1 drugs, with PepsiCo focusing on portion control, single-serve packaging, and fiber-enhanced products [5]. - Coca-Cola's incoming CEO emphasizes the need for faster innovation, including more protein in products and reduced sugar content [6]. - Executives view the rise of GLP-1 drugs as a structural change in consumer behavior, prompting significant investments in R&D, with General Mills planning to increase capital spending by up to 23% for nutrient-dense innovations [7].